Affiliation:
1. FSBI «Zakusov Institute of Pharmacology»
Abstract
In the article presented the results of research of the influence pharmacokinetics, bioavailability for CNS cyclo-L-prolylglycine to the manifestation of its main pharmacological effects in experimental animals.
Subject
Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science
Reference15 articles.
1. Boyko SS, Zherdev VP, Gudasheva ТA et al. Pharmacokinetics of dipeptide analog pyracetame wich nootropic activity GWS-111 and its main metabolites. Russian Journal of Experimental and Clinical Pharmacology.1997;72(2):3-6. (In Russ).
2. Boyko SS, Zherdev VP, Korotkov SA at al. Pharmacokinetics of new potencial dipeptide nootrope GWS-111 and its main metabolites in rat brain. Khimiko-Farmatsevicheskiy Zhurnal.2001;35(9):11-13. (In Russ).] DOI:10.1023/A^10140824082406443.
3. Gudasheva TA, Boyko SS, Akparov VKh et al. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Lett.1996;391(1-2): 149-152. DOI 10.1016/0014-5793(9600722-311.
4. Gudasheva TA, Boyko SS, Ostrovskaya RU et al. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. Eur J Drug Metab Pharmacokinet. 1997;22(3):245-52. DOI: 1007/BF03189814.
5. Gudasheva ТA, Ostrovskaya RU, Trofimov SS et al. New endogenous dipetide cycloprolylglicine is similar to piracetam by its mnemotropic selectivity. Bulletin of experimental biology and medicine. 1999;128 (10):411-413. (In Russ).]